Novo Nordisk stock combines a weak three year share price record with valuation checks that still lean supportive, which raises questions about how much pessimism is already reflected in today’s price
- Over the past three years the share price has declined 45.7%, which suggests investors have meaningfully reset their expectations for the business.
- Expectations around Novo Nordisk’s ability to grow and defend its position in the obesity treatment market can support the investment case. At the same time, competitive pressure highlighted by the recent Eli Lilly dispute over obesity drug advertising may weigh on how much investors are willing to pay.
- The stock screens as undervalued in 5 of 6 valuation checks, so the broader set of metrics leans toward the shares being priced cautiously rather than optimistically.
The issue now is whether that cautious pricing already reflects the competitive and legal risks around Novo Nordisk, or if the recent share price weakness still overstates them
Find out why Novo Nordisk’s -9.1% return over the last year is lagging behind its peers
Advertisement
Is Novo Nordisk a Bargain on Earnings?
P/E is usually a good starting point for a profitable, mature business like Novo Nordisk, where earnings are a key driver of value. Novo Nordisk currently trades on a P/E of about 11.7x, which is below the wider pharmaceuticals industry average of 16.8x and far below the peer group average near 51.4x. That puts the stock on a lower earnings multiple than many investors might expect for a major player in obesity and diabetes treatments
The fair P/E multiple implied by the model is 25.8x, which is more than double the current 11.7x. This gap suggests that, based on factors such as profitability profile, market position and sector risks, the shares trade at a meaningful discount to what the model would expect. Despite the legal dispute with Eli Lilly around obesity drug advertising, the current earnings multiple still prices Novo Nordisk below both the tailored fair multiple and key peers
On the P/E multiple, Novo Nordisk stock appears undervalued compared with both the modelled fair ratio and the broader pharmaceuticals sector
See what the numbers say about this price — find out in our valuation breakdown
The Novo Nordisk Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives build on this valuation puzzle around Novo Nordisk’s P/E and examine what would need to be true about Novo Nordisk’s future growth, margins and earnings for the stock to be worth substantially more or less than it is today, using a set of transparent scenarios that live on Simply Wall St’s Community page. Rather than rely on a single multiple or model output, each one lays out its assumptions so you can compare them with the company’s actual results over time
One of the top community narratives on Novo Nordisk: 49% undervalued
“Current sentiment has swung deeply negative, but expectations are now low, and the market appears to assign little to no value to Novo’s development-stage pipeline beyond Wegovy…”
Read one of the top narratives on Novo Nordisk
Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
The Bottom Line
Novo Nordisk screens as undervalued on earnings multiples, which suggests the market is pricing in a fair amount of caution already. The key question is whether that discount proves to be compensation for real competitive and legal risks or a gap that closes if sentiment improves. For now, the debate turns on one main assumption: whether Novo Nordisk can protect its obesity and diabetes franchise against rivals while maintaining the kind of profitability that might justify a higher P/E over time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
MI
mitchell_lawler
The Foxhole
Druckenmiller says cheap money’s days are numbered. Boring, self-funding companies could be the opportunity
1311
DE
devon_jd15012h
Leverage on its own is close to useless as a screen right now, because so much corporate debt was termed out at 2 to 3% and has not repriced. A business at three times leverage with nothing due until 2031 is in a completely different position from the same ratio rolling next year. Screen on weighted average maturity and the schedule behind it
LE
LeverageIsLovely13h
In my view, Insurance companies are best positioned for this
Mitchell Lawler
Market Insights
Which payment stocks actually get paid?
Every new payment app was supposed to kill Visa and Mastercard. Instead, they got bigger. So what does that mean for the payment stocks on your radar?
32
Aug 20, 2026
About NYSE:NVO
Novo Nordisk
Engages in the research and development, manufacture, and distribution of pharmaceutical products
See The Free Research Report
Undervalued with adequate balance sheet
See The Free Research Report
Similar Companies
Eli Lilly
NYSE:PFE
Pfizer
Market Insights
Which payment stocks actually get paid?MI
Mitchell Lawler
Picking portfolio winners takes more than hot airAN
Andrew Legget
What Korea’s market says about your index fundMI
Mitchell Lawler
Advertisement
Weekly Picks
RI
Rick_Orfordon Starfighters Space·19 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$522.8% undervalued
67followersusers have followed this narrative
·4commentsusers have commented on this narrative
·11likesusers have liked this narrative
TR
tripledubon Meta Platforms·22 days ago
The $135 Billion Bet That Should Make Every Shareholder Nervous
Fair Value:US$5862.7% undervalued
47followersusers have followed this narrative
·3commentsusers have commented on this narrative
·34likesusers have liked this narrative
TA
Taloson Voyager Technologies·16 days ago
The “Landlord of Orbit” – A Deep Value Play Ahead of the Starlab Era
Fair Value:US$385.291.0% undervalued
31followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
IV
Ivoedon Uber Technologies·10 days ago
Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides
Fair Value:US$11630.7% undervalued
7followersusers have followed this narrative
·0commentsusers have commented on this narrative
·3likesusers have liked this narrative
RecentlyUpdated Narratives
WO
woodworthfundon Kraft Heinz·about 5 hours ago
Kraft Heinz (KHC): Less Drama, More Ketchup
Fair Value:US$3527.7% undervalued
27followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
LU
LunaRodason DICK’S Sporting Goods·about 8 hours ago
DKS | DICK’S Sporting Goods: What They Said vs. What They Did
Fair Value:US$112.7710.2% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
PR
prajeeshprathapon Medpace Holdings·about 10 hours ago
Why Medpace Outperforms Competitors in the Mid-Sized Biotech Niche
Fair Value:US$53614.6% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28023.9% undervalued
352followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 2 months ago
A wonderful business at reasonable price
Fair Value:US$419.9117.1% overvalued
200followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
KI
KiwiInveston Amazon.com·4 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0945.1% undervalued
226followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
